Live
- EC rejects former MP Manda’s nomination
- Tirupati: ‘Work hard for the victory of Srinivasulu’
- Bad omen for BRS as more leaders look to jump ship
- Visakhapatnam: She may be CM’s sister, but Sharmila is rival, says Botcha Satyanarayana
- Modi is scared, he may cry on stage any time now: Rahul
- Harvey Weinstein's landmark #MeToo rape conviction overturned
- Indian-origin man killed while evading arrest in US
- WhatsApp will leave India, if asked to break encryption
- SC rejects pleas on 100% cross VVPAT verification
- Razole: Ample scope for tourism promotion in Konaseema says Pawan Kalyan
Just In
Hyderabad: Hetero gets DCGI nod to launch Covid drug
The generic version of Remdesivir will be marketed under brand name 'Covifor' in India
Hyderabad: City-based drug firm Hetero on Sunday said it has received approval from regulator DCGI to launch investigational antiviral drug Remdesivir for the treatment of Covid-19.
The company has received the manufacturing and marketing approval for Remdesivir from the Drug Controller General of India (DCGI) for the treatment of Covid-19, it said in a statement.
Hetero's generic version of Remdesivir will be marketed under the brand name 'Covifor' in India. The drug will be available in 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner, it said.
Asked about the price of the drug, Hetero Group of Companies MD Vamsi Krishna Bandi said it will be in the range of Rs 5,000-6,000 per dose.
Currently, the drug is being manufactured at the company's formulation facility in Hyderabad. The active pharmaceutical ingredient (API) is being made in the firm's Visakhapatnam facility, he added.
The drug will be available only through hospitals and government, and not the retail channel, Vamsi said.
The company is focused on providing one lakh doses in the next few weeks, and the production can be ramped up based on demand, he added.
The drug has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of Covid-19 in adults and children, hospitalised with severe symptoms of the disease, the company said.
"In the light of increasing Covid-19 cases in India, the approval of 'Covifor' (Remdesivir) can prove to be a game-changer given its positive clinical outcomes.
"Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country," Hetero Group of Companies Chairman B Partha Saradhi Reddy said.
The company is prepared for ensuring enough stocks to cater to the present needs, he added.
The product is being launched under a licensing agreement with Gilead Sciences Inc to expand access to Covid-19 treatment in low and middle-income countries, Hetero said.
In May, domestic pharma firms Hetero, Cipla and Jubilant Life Sciences had entered into non-exclusive licensing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of Remdesivir.
© 2024 Hyderabad Media House Limited/The Hans India. All rights reserved. Powered by hocalwire.com